This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients With Non-resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05841420
Recruitment Status : Recruiting
First Posted : May 3, 2023
Last Update Posted : July 27, 2023
Aarhus University Hospital
Odense University Hospital
Herlev and Gentofte Hospital
Gødstrup Hospital
Vejle Hospital
Information provided by (Responsible Party):
Morten Ladekarl, Aalborg University Hospital

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2025
Estimated Study Completion Date : June 2025